IL152655A0 - Method to increase class i presentation of exogenous antigens by human dendritic cells - Google Patents

Method to increase class i presentation of exogenous antigens by human dendritic cells

Info

Publication number
IL152655A0
IL152655A0 IL15265501A IL15265501A IL152655A0 IL 152655 A0 IL152655 A0 IL 152655A0 IL 15265501 A IL15265501 A IL 15265501A IL 15265501 A IL15265501 A IL 15265501A IL 152655 A0 IL152655 A0 IL 152655A0
Authority
IL
Israel
Prior art keywords
dendritic cells
presentation
processing
class
population
Prior art date
Application number
IL15265501A
Other languages
English (en)
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of IL152655A0 publication Critical patent/IL152655A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464819—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL15265501A 2000-05-12 2001-05-11 Method to increase class i presentation of exogenous antigens by human dendritic cells IL152655A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20375800P 2000-05-12 2000-05-12
PCT/US2001/015428 WO2001087325A1 (fr) 2000-05-12 2001-05-11 Methode permettant d'augmenter la presentation de classe i d'antigenes exogenes par les cellules dendritiques humaines

Publications (1)

Publication Number Publication Date
IL152655A0 true IL152655A0 (en) 2003-06-24

Family

ID=22755184

Family Applications (4)

Application Number Title Priority Date Filing Date
IL15265501A IL152655A0 (en) 2000-05-12 2001-05-11 Method to increase class i presentation of exogenous antigens by human dendritic cells
IL152655A IL152655A (en) 2000-05-12 2002-11-05 METHOD OF INCREASING TYPE i REPRESENTATION OF EXTERNAL ANTIGENS THROUGH HUMAN ORIGINAL DENDRITIC CELLS
IL231081A IL231081A (en) 2000-05-12 2014-02-23 METHOD FOR AMPLIFYING TYPE i REPRESENTATION OF EXTERNAL ANTIGENS THROUGH HUMAN-DENDRITIC CELLS
IL248493A IL248493A0 (en) 2000-05-12 2016-10-25 A method for increasing type 1 presentation of exogenous antigens using dendritic cells of human origin

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL152655A IL152655A (en) 2000-05-12 2002-11-05 METHOD OF INCREASING TYPE i REPRESENTATION OF EXTERNAL ANTIGENS THROUGH HUMAN ORIGINAL DENDRITIC CELLS
IL231081A IL231081A (en) 2000-05-12 2014-02-23 METHOD FOR AMPLIFYING TYPE i REPRESENTATION OF EXTERNAL ANTIGENS THROUGH HUMAN-DENDRITIC CELLS
IL248493A IL248493A0 (en) 2000-05-12 2016-10-25 A method for increasing type 1 presentation of exogenous antigens using dendritic cells of human origin

Country Status (12)

Country Link
US (2) US20030175247A1 (fr)
EP (2) EP2363139B1 (fr)
JP (4) JP4841794B2 (fr)
AT (1) ATE530193T1 (fr)
AU (3) AU5976001A (fr)
CA (1) CA2407104A1 (fr)
DK (2) DK2363139T3 (fr)
ES (2) ES2571979T3 (fr)
HK (1) HK1161977A1 (fr)
IL (4) IL152655A0 (fr)
NZ (1) NZ522807A (fr)
WO (1) WO2001087325A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2363139B1 (fr) * 2000-05-12 2016-03-02 NorthWest Biotherapeutics, Inc. Procédé pour augmenter la présentation de classe I d'antigènes exogènes par cellules dendritiques humaines
DK1441591T3 (en) * 2001-09-06 2017-05-22 Northwest Biotherapeutics Inc Compositions and Methods for Priming Monocytic Dendritic Cells and T-Cells for TH-1 Response
AU2013201707B2 (en) * 2001-09-06 2017-04-27 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
ATE454447T1 (de) * 2001-11-30 2010-01-15 Us Gov Health & Human Serv Peptidagonisten für prostata-spezifisches antigen und ihre verwendung
CA2469274A1 (fr) * 2001-12-10 2003-06-19 Kyogo Itoh Antigenes tumoraux
JP4624377B2 (ja) * 2001-12-10 2011-02-02 株式会社グリーンペプタイド 腫瘍抗原
EP2281004A4 (fr) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc Anticorps d'antigene membranaire specifique de la prostate et fragments de liaison a l'antigene
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
EP2727606A3 (fr) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Composés pour tuer des cellules cancéreuses exprimant psma et résistantes au taxane
WO2010065876A2 (fr) 2008-12-06 2010-06-10 The Board Of Regents Of The University Of Texas System Méthodes et compositions liés à des cellules dendritiques th-1
WO2010096693A2 (fr) * 2009-02-19 2010-08-26 Mayo Foundation For Medical Education And Research Procédés et matières pour générer des lymphocytes t
WO2011084479A1 (fr) * 2009-12-15 2011-07-14 Immuneregen Biosciences, Inc. Substance p et analogues de celle-ci utiles en tant que traitement adjuvant pour l'immunothérapie cellulaire adoptive
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
KR101985769B1 (ko) 2013-03-15 2019-06-04 동우 화인켐 주식회사 마스크리스 디지털 노광 방식을 통한 컬러 필터의 제조 방법
GB201315321D0 (en) * 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
CA2939093A1 (fr) * 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapie du cancer par combinaison de stimulation immunitaire locale et systemique
DE102015106810A1 (de) 2015-04-30 2016-11-03 Infineon Technologies Ag Implantierbare Vorrichtung und implantierbares System mit dieser
CN114246942A (zh) * 2020-09-24 2022-03-29 刘慧宁 肿瘤复合抗原、树突状细胞多价疫苗及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
CA2051092C (fr) 1990-09-12 2002-07-23 Stephen A. Livesey Methode et appareillage pour la cryopreservation, la stabilisation a sec et la rehydratation de suspensions biologiques
US5227471A (en) 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
WO1994002156A1 (fr) 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Procedes d'utilisation de cellules dendritiques pour activer des lymphocytes t
WO2001000225A1 (fr) * 1999-06-29 2001-01-04 Epimmune Inc. Peptides de liaison a hla et leurs utilisations
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
EP2363139B1 (fr) * 2000-05-12 2016-03-02 NorthWest Biotherapeutics, Inc. Procédé pour augmenter la présentation de classe I d'antigènes exogènes par cellules dendritiques humaines

Also Published As

Publication number Publication date
IL231081A0 (en) 2014-03-31
WO2001087325A1 (fr) 2001-11-22
ATE530193T1 (de) 2011-11-15
IL231081A (en) 2016-11-30
ES2375948T3 (es) 2012-03-07
AU2001259760B2 (en) 2006-10-05
EP2363139A1 (fr) 2011-09-07
NZ522807A (en) 2004-11-26
HK1161977A1 (zh) 2012-08-17
EP2363139B1 (fr) 2016-03-02
US20080171023A1 (en) 2008-07-17
AU5976001A (en) 2001-11-26
EP1292321A1 (fr) 2003-03-19
JP2014001244A (ja) 2014-01-09
JP2011225628A (ja) 2011-11-10
IL248493A0 (en) 2016-11-30
CA2407104A1 (fr) 2001-11-22
IL152655A (en) 2014-03-31
JP2015108018A (ja) 2015-06-11
EP1292321A4 (fr) 2005-09-21
ES2571979T3 (es) 2016-05-27
EP1292321B1 (fr) 2011-10-26
JP4841794B2 (ja) 2011-12-21
DK2363139T3 (en) 2016-05-30
AU2007200049A1 (en) 2007-01-25
DK1292321T3 (da) 2012-01-30
JP2003533486A (ja) 2003-11-11
US20030175247A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
IL248493A0 (en) A method for increasing type 1 presentation of exogenous antigens using dendritic cells of human origin
Filgueira et al. Human dendritic cells phagocytose and process Borrelia burgdorferi.
Hunter et al. Histochemical demonstration of enzymes separated by zone electrophoresis in starch gels
Feuerstein et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use
Duperrier et al. Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements
WO2006065495A3 (fr) Methodes d'utilisation d'il-21 pour l'immunotherapie adoptive et l'identification d'antigenes tumoraux
Tuschl et al. The expression of surface markers on dendritic cells as indicators for the sensitizing potential of chemicals
BRPI0212545A8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
RU2008122550A (ru) Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток
CA2368855A1 (fr) Differentiation de monocytes transformes en cellules dendritiques fonctionnelles
Lewalle et al. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli
MXPA05006042A (es) Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.
WO2002088328A8 (fr) Procede pour produire des cellules dendritiques humaines hautement actives a partir de monocytes
Steger et al. Peripheral blood dendritic cells reinduce proliferation in in vitro aged T cell populations
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
SI1509244T1 (sl) Nov postopek in spojina za izdelavo celične alogenične vakcine
JP2004520033A (ja) 分化拘束された成熟樹状細胞の調製用補助組成物
Chen et al. Interleukin-10-induced T cell unresponsiveness can be reversed by dendritic cell stimulation
WO2003073827A3 (fr) Procede de modulation de cellules dendritiques a l'aide d'adjuvants
Richters et al. Migratory properties and functional capacities of human skin dendritic cells
Putz et al. Monitoring of CD4+ and CD8+ T-cell responses after dendritic cell-based immunotherapy using CFSE dye dilution analysis
BIBERFELD Recruitment of monocyte derived dendritic cells ex vivo from SIV infected and non infected cynomolgus monkeys
Bender et al. Dendritic cells as immunogens for human CTL responses
MX2022004186A (es) Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.
Kočiková et al. Murine Langerhans cells cultured under serum-free conditions mature into potent stimulators of primary immune responses in vitro and in vivo